Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2004 1
2005 2
2006 1
2007 1
2009 1
2012 2
2013 3
2014 6
2015 7
2016 8
2017 10
2018 8
2019 13
2020 19
2021 7
2022 5
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 35537720

85 results

Results by year

Filters applied: . Clear all
Page 1
Prognostic Impact of Subsequent Acute Coronary Syndrome and Unplanned Revascularization on Long-Term Mortality After an Index Percutaneous Coronary Intervention: A Report From a Japanese Multicenter Registry.
Inohara T, Kohsaka S, Miyata H, Sawano M, Ueda I, Maekawa Y, Fukuda K, Jones PG, Cohen DJ, Zhao Z, Spertus JA, Smolderen KG. Inohara T, et al. J Am Heart Assoc. 2017 Oct 27;6(11):e006529. doi: 10.1161/JAHA.117.006529. J Am Heart Assoc. 2017. PMID: 29079567 Free PMC article.
Cardiovascular Events, Acute Hospitalizations, and Mortality in Patients With Type 2 Diabetes Mellitus Who Initiate Empagliflozin Versus Liraglutide: A Comparative Effectiveness Study.
Thomsen RW, Knudsen JS, Kahlert J, Baggesen LM, Lajer M, Holmgaard PH, Vedin O, Ustyugova A, Sørensen HT. Thomsen RW, et al. J Am Heart Assoc. 2021 Jun;10(11):e019356. doi: 10.1161/JAHA.120.019356. Epub 2021 May 25. J Am Heart Assoc. 2021. PMID: 34032121 Free PMC article.
Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME® randomised trial.
Verma S, Mazer CD, Fitchett D, Inzucchi SE, Pfarr E, George JT, Zinman B. Verma S, et al. Diabetologia. 2018 Aug;61(8):1712-1723. doi: 10.1007/s00125-018-4644-9. Epub 2018 May 19. Diabetologia. 2018. PMID: 29777264 Free PMC article. Clinical Trial.
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE; EMPA-REG OUTCOME Investigators. Zinman B, et al. N Engl J Med. 2015 Nov 26;373(22):2117-28. doi: 10.1056/NEJMoa1504720. Epub 2015 Sep 17. N Engl J Med. 2015. PMID: 26378978 Free article. Clinical Trial.
Use of prasugrel vs clopidogrel and outcomes in patients with and without diabetes mellitus presenting with acute coronary syndrome undergoing percutaneous coronary intervention.
Faggioni M, Baber U, Chandrasekhar J, Sartori S, Claessen BE, Rao SV, Vogel B, Effron MB, Poddar K, Farhan S, Kini A, Weintraub W, Toma C, Sorrentino S, Weiss S, Snyder C, Muhlestein JB, Kapadia S, Keller S, Strauss C, Aquino M, Baker B, Defranco A, Pocock S, Henry T, Mehran R. Faggioni M, et al. Int J Cardiol. 2019 Jan 15;275:31-35. doi: 10.1016/j.ijcard.2018.10.071. Epub 2018 Oct 25. Int J Cardiol. 2019. PMID: 30391067
85 results